Antibiotic gets positive FDA staff assessment

Shares of Forest Laboratories jumped on the news that FDA staffers found that their new antibiotic ceftaroline appears to be an effective therapy for skin infections and pneumonia. The staff review comes in advance of a key panel vote on the new antibiotic. Analysts have estimated that ceftaroline could garner $361 million in sales by 2014. Story

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.